Status:
UNKNOWN
Granulocyte Colony Stimulating Factor for for the Prevention of Febrile Neutropenia in Epithelial Ovarian Cancer
Lead Sponsor:
Lei Li
Collaborating Sponsors:
Beijing Hospital
China-Japan Friendship Hospital
Conditions:
Chemotherapy-induced Neutropenia
Febrile Neutropenia, Drug-Induced
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
This study aims to analyze the effects of long-acting versus short-acting granulocyte colony stimulating factor (G-CSF) on the prevention febrile neutropenia (FN) in epithelial ovarian cancer patients...
Eligibility Criteria
Inclusion
- With definitive pathological results of epithelial ovarian cancer
- With an Eastern Cooperative Oncology Group (ECOG) performance status score of 0-2
- Aged 18 or older
- Receiving 3-4 weeks per cycle of platinum-based chemotherapy with or without debulking surgery
- Regularly followed up in the study centers
- Provided consent for participation.
Exclusion
- Failure to meet all the inclusion criteria
- Non-compliance with the study protocols
- With a history of chemotherapy or pelvic radiotherapy for malignancies
- Presence of immunosuppressive diseases such as organ transplantation or acquired immune deficiency syndrome
- Treated with weekly chemotherapy regimens
- Presence of hematological disorders
Key Trial Info
Start Date :
October 1 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 1 2020
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT04101760
Start Date
October 1 2019
End Date
October 1 2020
Last Update
October 8 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Lei Li
Beijing, Beijing Municipality, China, 100730